Daclizumab | Aplastic Anemia and MDS International Foundation

Daclizumab

An immunosuppressant, this drug lowers the body's immune response.
Brand name: 
Zenapax

It is approved by the U.S. Food and Drug Administration (FDA) for use in transplant patients to reduce the chance of organ rejection. Currently, researchers are studying daclizumab for treating aplastic anemia to determine whether it will be effective and safe to use.

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.